Axa Pharmaceuticals has been awarded the second orphan drug title by the FDA: Bcl-2 inhibitor APG-2575 for the treatment of Fahrenheit polycypproteinemia.

as !---- centage Pharma has announced that its new Bcl-2 inhibitor, APG-2575, is treating Fahrenheit polycylobinemia (WM), and has been awarded the orphan drug (ODD) by the U.SFood and Drug Administration (FDA)this is the second time that Axa Pharmaceuticals has been awarded THE ODD title by the FDAabout Fahrenheit polycypinemia WM is a lymphocytic lymphoma characterized by lymphocyte cells in the bone marrow and elevated immunoglobulin M (IgM)WM as a rare disease, accounting for less than 2% of all non-Hodgkin's lymphoma (NHL) patients in the United Statesthe current WM therapy local response rate (VGPR) is about 20% or less, most patients experience disease progression after the initial responsethe median age of 70 at the time of diagnosis of WM patients, most of them are unable to receive existing treatments due to poor healthnew oral Bcl-2 beta selective inhibitor developed by Ascentage PharmaAPG-2575 is designed to treat a variety of malignant tumors in the blood system by selectively blocking Bcl-2 to restore normal apoptosis of cancer cellsSince March 2020, the company has been approved for APG-2575 Ib/II studies in China, Australia and the United States, and is advancing the clinical development of APG-2575 in a variety of malignant diseases of the blood system, including refractive chronic lymphocytic leukemia, small lymphocyte lymphocytes, Fahrenheit hemophilidemia, recurrent/refractive multiple myeloma and recurrent/difficult-treated acute myeloid leukemia"The FDA's award of WMOD for aPG-2575 treatment marks an important milestone in the global development and commercialization of the drug," said DrDajun Yang, Chairman and CEO ofAXSaall ODD policies will support and assist us in accelerating the global clinical development of APG-2575, and we hope to benefit patients in the near future"